Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055402 | 0.89 | CYP17A1 (0.59) | CYP17A1ALDH1A1MAPK14PSMB8NAMPT | |
| SCHEMBL20057652 | 0.87 | HDAC3 (0.49) | CYP17A1MAPK14NAMPTKMT2ACA12 | |
| SCHEMBL730480 | 0.85 | CYP17A1 (0.57) | CYP17A1MAPK14PSMB8NAMPTMAPKAPK2 | |
| SCHEMBL20057547 | 0.84 | ALDH1A1 (0.46) | CYP17A1ALDH1A1MAPK14PSMB8NAMPT | |
| SCHEMBL3461792 | 0.84 | SMN1; SMN2 (0.59) | CYP17A1MAPK14NAMPTKMT2ASMN1; SMN2 | |
| SCHEMBL23619661 | 0.83 | SMN1; SMN2 (0.62) | CYP17A1ALDH1A1PSMB8NAMPTCA12 | |
| SCHEMBL20865536 | 0.83 | CYP17A1 (0.68) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL8258345 | 0.83 | NAMPT (0.59) | CYP17A1ALDH1A1MAPK14NAMPTPTPN11 | |
| SCHEMBL13886030 | 0.83 | ALDH1A1 (0.54) | CYP17A1ALDH1A1PSMB8NAMPTMAPKAPK2 | |
| SCHEMBL20815511 | 0.83 | ALDH1A1 (0.56) | CYP17A1ALDH1A1MAPK14KMT2AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | CYP17A1 911/4885ALDH1A1 968/4885MAPK14 2028/4885 |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | HCRTR2, HCRTR1, NPSR1 | CYP17A1 911/4885ALDH1A1 968/4885MAPK14 2028/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CYP17A1 1047/4885ALDH1A1 1264/4885MAPK14 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.